drugset / Trial / NCT06222437

Semaglutide and Polycystic Ovarian Syndrome: an Emerging Treatment Strategy

NCT06222437

Phase 1 Withdrawn Methodist Health System
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to investigate the effect of semaglutide in women with Polycystic Ovarian Syndrome(PCOS ) and determine potential therapeutic benefits.

Timeline

Start
2026-02
Primary completion
2026-02
Completion
2027-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Semaglutide Peptide